 II, MPS III A and MPS III B. To complement the studies with human subjects, a drug (suramin) induced animal model of MPS has been developed and a canine model, (natural), of MPS I (alpha-L-iduronidase deficiency), has been fully characterized. In an
II, MPS III A and MPS III B. To complement the studies with human subjects, a drug (suramin) induced animal model of MPS has been develop and a canine exemplar, (natural), of MPS I (alpha - L - iduronidase deficiency), has been in full characterized. In an
 II, MPS III A and MPS III B. To complement jhw studmes witg human rubjects, a drug (suramin) indured qnimao model of MPS has beev developvd and a xaniie model, (natural), of MPS L (alpgw-L-idbrinidase deficigncy), has beet fully characdefived. In an
II, MPS III A and MPS III complement studies with subjects, a drug MPS been developed and canine model, (natural), MPS I (alpha-L-iduronidase deficiency), has been characterized. In an
 II, MPS III A and MPS III B. To compLement the sTudieS wiTh hUmAn suBjecTs, a drug (suramin) INducEd animal model of MPS has bEen deVeLOped ANd A caniNe model, (NAtURAl), oF MpS i (alPhA-l-iDuronIdaSe deficIency), has beEn fUlLy characteriZEd. in an
 II, MPS III A and MPS III  B. To com pleme ntthe  s tudi es w ith human subj e cts,  a drug (suramin) indu ced a ni m al m o de l ofMPS has be e n  de ve lo ped  a n da can ine  model,  (natural) , o fMPS I (alpha - L- iduronidas e d eficiency),has  beenfu lly chara cte rized . In a n 
 II,_MPS III_A and MPS III_B. To_complement_the studies_with_human subjects, a_drug (suramin) induced_animal model of MPS_has been developed_and_a canine model, (natural), of MPS I (alpha-L-iduronidase deficiency), has been fully characterized. In_an